Back to today’s briefing

Story perspectives

GLP-1 Drugs May Mislead PET-CT Scan Results

10/8/2025

28 7

Summary

Story summary

Glucagon-like peptide-1 (GLP-1) weight-loss drugs, including Ozempic and Wegovy, may alter FDG uptake in PET-CT scans.
Alliance Medical's study found abnormal FDG uptake patterns in PET-CT scans of patients using these GLP-1 drugs.
Misinterpretation could trigger unnecessary tests and patient anxiety; no national or international guidelines exist.
Further research is needed to confirm findings and guide protocols.

1 of 1

Story summary

Glucagon-like peptide-1 (GLP-1) weight-loss drugs, including Ozempic and Wegovy, may alter FDG uptake in PET-CT scans.
Alliance Medical's study found abnormal FDG uptake patterns in PET-CT scans of patients using these GLP-1 drugs.
Misinterpretation could trigger unnecessary tests and patient anxiety; no national or international guidelines exist.
Further research is needed to confirm findings and guide protocols.